title: Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
authors.affiliation: Centre for Eye Research Australia (CERA), Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, Victoria, Australia.
authors.forename: Sanjeewa
authors.initials: S
authors.lastname: Wickremasinghe
authors.forename: Farshad
authors.initials: F
authors.lastname: Abedi
authors.forename: Sukhpal S
authors.initials: SS
authors.lastname: Sandhu
authors.forename: Robyn
authors.initials: R
authors.lastname: Guymer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D006801:Humans; D000069579:Ranibizumab; D019233:Retreatment; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab